Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.
Bergerat
J P
JP
Service d'Onco-Hématologie, CHU de Strasbourg, France.
Ford
J
J
Herbrecht
R
R
Dufour
P
P
Oberling
F
F
Jacqmin
D
D
Bollack
C
C
Prevot
G
G
Salze
P
P
Jurascheck
F
F
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011994:Recombinant Proteins; D012074:Remission Induction; D015996:Survival Rate; D014747:Vinblastine / Q000627:therapeutic use*
D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins; D014747:Vinblastine